OmicsChart

Meet OmicsChart founders at the events this autumn. Here is where you can find us: 📅 October 2-3:  Sifted Summit, London 📅 October 9-10: BioTechX, Basel   📅 October 15-17:  Festival of Biologics, Basel #scRNAseq #multiomics #transcriptomics #genomics #omics #proteomics #metabolomics #RNAseq #oncology #CancerResearch #PrecisionOncology #oncologyresearch #cancerbiology #translationalbiology #translationaloncology #immunooncology #BiomarkerDiscovery #DrugDiscovery #PrecisionMedicine #targetdiscovery #rwd #realworlddata #rwe #clinicaltrials #bioinformatics #computationalbiology #biotech #startup #techbio #healthtech  

Thank you for warm welcome at Festival of Biologics in Basel this week, and opportunity to showcase OmicsChart's innovation in omics data for #oncology translational research. Great to meet my former colleague Christine Rothe, who is now leading the development at iOmx Therapeutics AG and presented at FoB the amazing progress of IOMX-0675! Looks like my mini-reunions with Pieris days continue :) looking forward to continue discussions with OmicsChart's new friends as well! Now we are back to building! Building clients and investors relationships, building the team, and building PREON!

OmicsChart will be exhibiting at Biotech X Europe in Basel next week! This is a great opportunity to connect with industry leaders, explore innovations in biotechnology, and showcase how our cutting-edge data solutions are driving advancements in the oncology. 🔬 If you're attending, don't miss the chance to meet our team! Please reach out to our founders for a chat – we would love to discuss how OmicsChart can accelerate your drug development efforts. Looking forward to seeing you there! 🙌 #BiotechX #OmicsChart #BiotechInnovation #Basel #Networking #Omics #DataAnalytics #Biotechnology #LifeSciences

🧬 𝙊𝙢𝙞𝙘𝙨 𝙀𝙭𝙥𝙚𝙧𝙞𝙢𝙚𝙣𝙩𝙨 & 𝘼𝙣𝙖𝙡𝙮𝙨𝙞𝙨 🧬 𝙞𝙣 💊𝘾𝙖𝙣𝙘𝙚𝙧 𝘿𝙧𝙪𝙜 𝘿𝙚𝙫𝙚𝙡𝙤𝙥𝙢𝙚𝙣𝙩 💊 - 𝙬𝙝𝙖𝙩 𝙮𝙤𝙪 𝙣𝙚𝙚𝙙 𝙩𝙤 𝙠𝙣𝙤𝙬 𝙖𝙗𝙤𝙪𝙩 ... 🩺 𝙌𝙪𝙖𝙡𝙞𝙩𝙮 𝙤𝙛 𝙎𝙖𝙢𝙥𝙡𝙚𝙨 𝙖𝙣𝙙 𝘿𝙖𝙩𝙖 🩺 : Two most important factors that must be considered in the analysis of omics data from cancer patients: 𝗧𝘂𝗺𝗼𝗿 𝗰𝗼𝗻𝘁𝗲𝗻𝘁 𝗼𝗳 𝗮 𝗯𝗶𝗼𝗽𝘀𝘆. Genomics and transcriptomics generate a readout based on all the molecules present in the sample: from tumor or infiltrating immune cells or surrounding stromal or tumor-adjacent healthy tissue. Make sure this information is included in the analysis and is presented alongside the results to exclude variability associated with variable tumor content 𝗣𝗿𝗲𝘀𝗲𝗿𝘃𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝘁𝗵𝗲 𝘀𝗮𝗺𝗽𝗹𝗲. Some of the omics technologies can only be applied to fresh-frozen samples, but fresh-frozen samples are challenging to collect and divide for multiple omics technologies, especially when multiple people are involved in sample collection, preservation and transport. Preservation quality can be a confounding factor, and shall be included in the analysis. 𝘕𝘦𝘹𝘵 𝘸𝘦𝘦𝘬: 𝘖𝘮𝘪𝘤𝘴 𝘦𝘹𝘱𝘦𝘳𝘪𝘮𝘦𝘯𝘵𝘴 & 𝘢𝘯𝘢𝘭𝘺𝘴𝘪𝘴 𝘪𝘯 𝘥𝘳𝘶𝘨 𝘥𝘦𝘷𝘦𝘭𝘰𝘱𝘮𝘦𝘯𝘵 - 𝘸𝘩𝘢𝘵 𝘺𝘰𝘶 𝘯𝘦𝘦𝘥 𝘵𝘰 𝘬𝘯𝘰𝘸 𝘢𝘣𝘰𝘶𝘵 ✅ 𝘊𝘰𝘮𝘱𝘶𝘵𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘳𝘦𝘲𝘶𝘪𝘳𝘦𝘮𝘦𝘯𝘵𝘴 ✅ #omics #biomarkers #drugdevelopment #transcriptomics #genomics #cancer #proteomics #GCP

🧬 𝙊𝙢𝙞𝙘𝙨 𝙀𝙭𝙥𝙚𝙧𝙞𝙢𝙚𝙣𝙩𝙨 & 𝘼𝙣𝙖𝙡𝙮𝙨𝙞𝙨 🧬 𝙞𝙣 💊𝘾𝙖𝙣𝙘𝙚𝙧 𝘿𝙧𝙪𝙜 𝘿𝙚𝙫𝙚𝙡𝙤𝙥𝙢𝙚𝙣𝙩 💊 - 𝙬𝙝𝙖𝙩 𝙮𝙤𝙪 𝙣𝙚𝙚𝙙 𝙩𝙤 𝙠𝙣𝙤𝙬 𝙖𝙗𝙤𝙪𝙩 ... 🩺 𝙌𝙪𝙖𝙡𝙞𝙩𝙮 𝙤𝙛 𝙎𝙖𝙢𝙥𝙡𝙚𝙨 𝙖𝙣𝙙 𝘿𝙖𝙩𝙖 🩺 : Two most important factors that must be considered in the analysis of omics data from cancer patients: 𝗧𝘂𝗺𝗼𝗿 𝗰𝗼𝗻𝘁𝗲𝗻𝘁 𝗼𝗳 𝗮 𝗯𝗶𝗼𝗽𝘀𝘆. Genomics and transcriptomics generate a readout based on all the molecules present in the sample: from tumor or infiltrating immune cells or surrounding stromal or tumor-adjacent healthy tissue. Make sure this information is included in the analysis and is presented alongside the results to exclude variability associated with variable tumor content 𝗣𝗿𝗲𝘀𝗲𝗿𝘃𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝘁𝗵𝗲 𝘀𝗮𝗺𝗽𝗹𝗲. Some of the omics technologies can only be applied to fresh-frozen samples, but fresh-frozen samples are challenging to collect and divide for multiple omics technologies, especially when multiple people are involved in sample collection, preservation and transport. Preservation quality can be a confounding factor, and shall be included in the analysis. 𝘕𝘦𝘹𝘵 𝘸𝘦𝘦𝘬: 𝘖𝘮𝘪𝘤𝘴 𝘦𝘹𝘱𝘦𝘳𝘪𝘮𝘦𝘯𝘵𝘴 & 𝘢𝘯𝘢𝘭𝘺𝘴𝘪𝘴 𝘪𝘯 𝘥𝘳𝘶𝘨 𝘥𝘦𝘷𝘦𝘭𝘰𝘱𝘮𝘦𝘯𝘵 - 𝘸𝘩𝘢𝘵 𝘺𝘰𝘶 𝘯𝘦𝘦𝘥 𝘵𝘰 𝘬𝘯𝘰𝘸 𝘢𝘣𝘰𝘶𝘵 ✅ 𝘊𝘰𝘮𝘱𝘶𝘵𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘳𝘦𝘲𝘶𝘪𝘳𝘦𝘮𝘦𝘯𝘵𝘴 ✅ #omics #biomarkers #drugdevelopment #transcriptomics #genomics #cancer #proteomics #GCP

20 RWE Startups to keep an eye on into 2025! Some exciting companies listed, to name a few; - Arcturis - Cornerstone AI - OmicsChart - Wemedoo AG - Comsentimento Full article below;

🧬 𝙊𝙢𝙞𝙘𝙨 𝙀𝙭𝙥𝙚𝙧𝙞𝙢𝙚𝙣𝙩𝙨 & 𝘼𝙣𝙖𝙡𝙮𝙨𝙞𝙨 🧬 𝙞𝙣 💊𝘾𝙖𝙣𝙘𝙚𝙧 𝘿𝙧𝙪𝙜 𝘿𝙚𝙫𝙚𝙡𝙤𝙥𝙢𝙚𝙣𝙩 💊 - 𝙬𝙝𝙖𝙩 𝙮𝙤𝙪 𝙣𝙚𝙚𝙙 𝙩𝙤 𝙠𝙣𝙤𝙬 𝙖𝙗𝙤𝙪𝙩 ... 🩸 𝘽𝙞𝙤𝙨𝙥𝙚𝙘𝙞𝙢𝙚𝙣 𝙎𝙤𝙪𝙧𝙘𝙚🩸: 🧫 𝗖𝗲𝗹𝗹 𝗹𝗶𝗻𝗲 material is generally abundant, with high quality preservation, so technologies that are more sensitive to degradation (like #transcriptomics family) will be perfect here for the discovery stage (novel targets identification). 🐁 𝗠𝗼𝘂𝘀𝗲 𝗺𝗼𝗱𝗲𝗹𝘀 are a great way to evaluate your drugs in a complex organism, but the type of mouse model has to be described in detail to evaluate appropriate processing pipeline, to distinguish mouse-derived analytes from human-derived analytes.  💉 𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝘁𝘂𝗺𝗼𝗿 𝗯𝗶𝗼𝗽𝘀𝘆 material is hard to collect, usually scarce (only limited amount is available), heterogeneous (all kinds of tumors, variable tumor content in the sample) and with various quality of preservation (usually FFPE). This forces to make hard compromises on biomarkers to evaluate in patient samples, and types of technologies that are applicable. 🩸 𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗯𝗹𝗼𝗼𝗱 𝗮𝗻𝗱 𝗯𝗼𝗱𝗶𝗹𝘆 𝗳𝗹𝘂𝗶𝗱𝘀 usually abundantly available as they are easier to collect, but the clinical relevance/interpretation of omics biomarkers is less established. ❗️𝗠𝗮𝗸𝗲 𝘀𝘂𝗿𝗲 𝘁𝗼 𝗰𝗼𝗺𝗺𝘂𝗻𝗶𝗰𝗮𝘁𝗲 𝘁𝗵𝗲𝘀𝗲 𝗰𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 𝘁𝗼 𝘆𝗼𝘂𝗿 𝗯𝗶𝗼𝗶𝗻𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝗰𝗶𝗮𝗻, 𝗼𝗿 𝗶𝗳 𝘆𝗼𝘂 𝗮𝗿𝗲 𝘁𝗵𝗲 𝗯𝗶𝗼𝗶𝗻𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝗰𝗶𝗮𝗻 – 𝗿𝗲𝗺𝗲𝗺𝗯𝗲𝗿 𝘁𝗵𝗮𝘁 𝘁𝗵𝗲𝘀𝗲 𝗮𝗿𝗲 𝘁𝗵𝗲 𝗽𝗿𝗮𝗰𝘁𝗶𝗰𝗮𝗹 𝗹𝗶𝗺𝗶𝘁𝗮𝘁𝗶𝗼𝗻𝘀 𝘁𝗵𝗮𝘁 𝗻𝗲𝗲𝗱 𝘁𝗼 𝗯𝗲 𝗶𝗻𝗰𝗼𝗿𝗽𝗼𝗿𝗮𝘁𝗲𝗱 𝗶𝗻𝘁𝗼 𝘆𝗼𝘂𝗿 𝗮𝗻𝗮𝗹𝘆𝘀𝗶𝘀 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝘆. 𝘕𝘦𝘹𝘵 𝘸𝘦𝘦𝘬: 𝘖𝘮𝘪𝘤𝘴 𝘦𝘹𝘱𝘦𝘳𝘪𝘮𝘦𝘯𝘵𝘴 & 𝘢𝘯𝘢𝘭𝘺𝘴𝘪𝘴 𝘪𝘯 𝘥𝘳𝘶𝘨 𝘥𝘦𝘷𝘦𝘭𝘰𝘱𝘮𝘦𝘯𝘵 - 𝘸𝘩𝘢𝘵 𝘺𝘰𝘶 𝘯𝘦𝘦𝘥 𝘵𝘰 𝘬𝘯𝘰𝘸 𝘢𝘣𝘰𝘶𝘵 🧬 𝘖𝘮𝘪𝘤𝘴 𝘛𝘦𝘤𝘩𝘯𝘰𝘭𝘰𝘨𝘪𝘦𝘴 🧬 OmicsChart #omics #biomarkers #drugdevelopment #transcriptomics #genomics #cancer #proteomics

3 weeks ago, #HLTHEurope showed that #Europe 🇪🇺 is truly a hub of #digitalhealth innovation. However, a common conversation topic was how to stand out & expand internationally 🌎 - particularly to US? 🤷♂️ This isn't the first time I've heard this, and it certainly won't be the last. 😅 However, a primary goal at PharmStars is to directly connect startups with global pharma companies active in the US. Hence why I'm always excited when European founders apply! 🚀 👌 If you or someone you know would like to be a part of our innovations in clinical trials #Fall2024 cohort and get connected to the likes of: Alexion Pharmaceuticals, Inc. | AstraZeneca   | Boehringer Ingelheim |  Eli Lilly and Company | Novo Nordisk | Sumitomo Pharma America, Inc. then find out more and apply here (deadline is Monday 15th July!): 👉 www.pharmstars.com 👈 You'd be joining an incredible group of #European PharmStars Alumni featuring high-growth startups from: #France 🇫🇷 - Scienta Lab #Germany 🇩🇪 - OmicsChart, Orbit Health #Ireland 🇮🇪 - Akkure Genomics, Head Diagnostics, My Moves Matter #Israel 🇮🇱 - Panacea-ml #Latvia 🇱🇻 - Longenesis #Poland 🇵🇱 - Saventic Health #Portugal 🇵🇹 - Promptly Health #Spain 🇪🇸 - acceXible, MiMARK #UK 🇬🇧 - Neuroute, Samphire Neuroscience, Sano Genetics, uMed, viO HealthTech Retis, EBN - European Business & Innovation Centre Network, Enterprise Ireland, TechIreland, Netherlands Enterprise Agency , HEALTH HUB UTRECHT, Netherlands Innovation Network in Boston, Health Cluster Portugal, Business France, Wirtschaftsagentur Wien, Health Hub Vienna, LISAvienna, health innovation hub (hih), German Accelerator, EIT Health, Invest in Latvia

Ready to kick-off #Curious2024 and share our innovative approach to federated omics data sharing for #cancer research OmicsChart #oncology #genomics

This week we have an honor to present OmicsChart at a Startup Fair at #Curious2024 alongside innovators in #deeptech in health, chemistry, climate, mobility, space and more. #innovation #staycurious #oncology #drugdevelopment